Most read article(s)

Open Access
REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics
R. L. Carhart-Harris and K. J. Friston
Eric L. Barker, ASSOCIATE EDITOR

Pharmacological Reviews July 2019, 71 (3) 316-344; DOI: https://doi.org/10.1124/pr.118.017160
Open Access
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Ai-Ming Yu, Young Hee Choi and Mei-Juan Tu
RHIAN M. TOUYZ, ASSOCIATE EDITOR

Pharmacological Reviews October 2020, 72 (4) 862-898; DOI: https://doi.org/10.1124/pr.120.019554
You have access
Psychedelics
David E. Nichols
Eric L. Barker, ASSOCIATE EDITOR

Pharmacological Reviews April 2016, 68 (2) 264-355; DOI: https://doi.org/10.1124/pr.115.011478
Open Access
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Antonio Inserra, Danilo De Gregorio and Gabriella Gobbi
Michael Nader, ASSOCIATE EDITOR

Pharmacological Reviews January 2021, 73 (1) 202-277; DOI: https://doi.org/10.1124/pharmrev.120.000056
You have access
Interindividual Differences in Caffeine Metabolism and Factors Driving Caffeine Consumption
Astrid Nehlig
Stephen P. H. Alexander, ASSOCIATE EDITOR

Pharmacological Reviews April 2018, 70 (2) 384-411; DOI: https://doi.org/10.1124/pr.117.014407
Open Access
Pharmacological Inhibition of the Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome with MCC950
Sarah E. Corcoran, Reena Halai and Matthew A. Cooper
Clive Page, ASSOCIATE EDITOR

Pharmacological Reviews July 2021, 73 (3) 968-1000; DOI: https://doi.org/10.1124/pharmrev.120.000171
Open Access
Is Oxytocin “Nature’s Medicine”?
C. Sue Carter, William M. Kenkel, Evan L. MacLean, Steven R. Wilson, Allison M. Perkeybile, Jason R. Yee, Craig F. Ferris, Hossein P. Nazarloo, Stephen W. Porges, John M. Davis, Jessica J. Connelly and Marcy A. Kingsbury
Robert Dantzer, ASSOCIATE EDITOR

Pharmacological Reviews October 2020, 72 (4) 829-861; DOI: https://doi.org/10.1124/pr.120.019398
Open Access
Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution
Uddalak Bharadwaj, Moses M. Kasembeli, Prema Robinson and David J. Tweardy
Richard D. Ye, ASSOCIATE EDITOR

Pharmacological Reviews April 2020, 72 (2) 486-526; DOI: https://doi.org/10.1124/pr.119.018440
You have access
The Psychopharmacology of Obsessive-Compulsive Disorder: A Preclinical Roadmap
Henry Szechtman, Brian H. Harvey, Erik Z. Woody and Kurt Leroy Hoffman
Jeffrey M. Witkin, ASSOCIATE EDITOR

Pharmacological Reviews January 2020, 72 (1) 80-151; DOI: https://doi.org/10.1124/pr.119.017772
Open Access
Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options
Wolfgang Löscher, Heidrun Potschka, Sanjay M. Sisodiya and Annamaria Vezzani
Eric L. Barker, ASSOCIATE EDITOR

Pharmacological Reviews July 2020, 72 (3) 606-638; DOI: https://doi.org/10.1124/pr.120.019539

Main menu

User menu

Search

Most read article(s)

Pages

Navigate

More Information

ASPET's Other Journals